Drug delivery and translational researchSep 4, 2025

Targeted delivery of an immune-boosting fusion protein using mRNA nanoparticles triggers strong anti-tumor response in liver cancer

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 2, 2026

Abstract

mRNA-LNP-mediated delivery of the IFN-α/anti-glypican-3 fusion protein achieved a significant inhibition of tumor growth and prolonged median survival in mouse models of hepatocellular carcinoma.

In vitro experiments showed successful protein expression and specific binding to glypican-3 (GPC3) by the mRNA-LNP platform.
In vivo studies indicated significant tumor growth inhibition and increased intratumoral CD8⁺ T cell and NK cell infiltration following treatment with the fusion protein.
Combination therapy with a PD-1 antibody enhanced antitumor effects, which were primarily associated with CD8⁺ T cell infiltration.
Safety evaluations in human IFNAR transgenic mice demonstrated good tolerability for single doses of 1-10 mpk, with transient biomarker changes.
The maximum tolerated dose (MTD) was identified as 6 mpk, which is at least 40-fold higher than the minimal effective dose of 0.15 mpk.

Simplified

This study aimed to utilize the mRNA-lipid nanoparticle (mRNA-LNP) platform to achieve in situ hepatic expression of an interferon-α (IFN-α)/anti-glypican-3 (anti-GPC3) fusion protein (GPA01), enhancing IFN-α targeting and antitumor activity to provide a precision therapy strategy for GPC3-positive hepatocellular carcinoma (HCC). mRNA encoding a GPC-3/IFN-α bispecific fusion protein was designed and synthesized, encapsulated in lipid nanoparticles, and transfected into HCC cell lines (HepG2) for in vitro characterization of protein expression, binding activity, and gene induction. Orthotopic HCC models (HepG2-luc) and subcutaneous tumor model (Hepa 1-6/hGPC3-hi) were established in mice to evaluate tumor growth, survival, and immune cell infiltration following treatment with mRNA-LNP or control agents. Safety was assessed in human IFNAR transgenic mice. In vitro experiments demonstrated successful transfection and bioactive fusion protein expression by mRNA-LNP, with transfected supernatants showing specific GPC3 binding and interferon-stimulated gene (ISG) induction. In vivo studies revealed that GPC-3/IFN-α mRNA-LNP significantly inhibited tumor growth, prolonged median survival, and increased intratumoral CD8⁺ T cell and NK cell infiltration compared to controls, with favorable safety profiles. Combination therapy with PD-1 antibody (PD-1 Ab) exerted synergistic antitumor effects, primarily dependent on CD8⁺ T cell infiltration. Safety evaluations in human IFNAR transgenic mice showed good tolerability at single doses of 1-10 mpk, with transient changes in select biomarkers. Repeated dosing (6 or 10 mpk) identified a maximum tolerated dose (MTD) of 6 mpk, at least 40-fold higher than the minimal effective dose (MED, 0.15 mpk). mRNA-LNP-mediated delivery of IFN-α-anti-GPC3 fusion protein achieves targeted in situ hepatic expression, significantly enhancing antitumor activity with a broad therapeutic window. This strategy offers a novel approach for precision immunotherapy in HCC, holding substantial potential for clinical translation.

Full Text

Full text is available at the source.

View Full Text ↗

Targeted delivery of an immune-boosting fusion protein using mRNA nanoparticles triggers strong anti-tumor response in liver cancer

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief